SIMR, LLC: IQ 2021 Update

We’ve not written about SIMR, LLC (aka STATinMED Research) before but the life sciences data company has been underperforming since IIIQ 2019, when we first noted a drop in the equity valuation of the BDCs that held those positions. The situation got worse in 2020 with first lien debt discounted by increasing percentages and the equity written to zero. At IQ 2021, the debt was discounted (10%)-(15%) by the two BDCs with a position: Capital Southwest (CSWC) and non-traded Cion Investment. Overall, BDC exposure at cost was $45.4mn and FMV $27.1mn.

That FMV versus cost alone is cause for concern. However, we also note that back in 2019 the lenders ramped up pricing from LIBOR + 9.00% to LIBOR + 17.00% plus a 2.00% floor ! That’s an all-in rate of nearly 20% and a sure sign that all is not well. For CSWC, that’s a worrying $2.6mn of annual investment income at risk if SIMR should default and even more at Cion: $3.4mn.

We do not know what’s gone wrong at SIMR – which was acquired in 2018 by Ancor Capital Partners. CSWC has been mum about the situation and Cion does not hold conference calls. The public record has provided no clues. We have rated the company CCR 4, but have not added the name to our Trending List as the valuation has been stable of late, and there is no obvious catalyst for a change in value or income in the IIQ 2021 results. However, given the high amount of income at risk (equal – for CSWC – to 8.2% of its FY 2021 Net Investment Income), this is a company whose fortunes are worth tracking regularly.